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Background
Ischemic stroke is the second leading cause of death
worldwide. Only one moderately effective therapy exists,
albeit with contraindications that exclude 90% of the
patients. This medical need contrasts with a high failure
rate of more than 1,000 pre-clinical drug candidates for
stroke therapies. Thus, there is a need for translatable
mechanisms of neuroprotection and more rigid thresholds
of relevance in pre-clinical stroke models. In many settings
of ischemia, vasodilation to increase perfusion is a suitable
approach; yet in stroke it bears the risk of systemic hypo-
tension, shunting of blood from the ischemic to healthy
areas, increased infarcts and eventually reduced survival.
One potentially innovative and mechanism-based
approach are sGC activators, as they represent disease-
specific vasodilators that are potentiated under conditions
of oxidative stress and have microvascular selectivity e.g.
to unload the acutely failing heart.
Results
Here we show that in the experimental stroke model of
transient middle cerebral artery occlusion (tMCAO) in the
mouse, substantial oxidative stress leads to 100% mortality
after one week. However, post-stroke treatment with the
sGC activator, BAY 60-2770, increased cerebral blood
flow, prevented the breakdown of the blood brain barrier
together with less apoptosis and smaller infarct volumes.
This was associated with an increase in the biomarkers of
sGC-cGMP signaling, P-VASP. As expected this increase
in cGMP was not affecting oxidative stress directly but
surprisingly exerted a potent anti-inflammatory response
on microglia activation and neutrophil infiltration and
inhibited neuronal apoptosis. Systemic blood pressure, a
potential confounder, was not affected. Besides these sur-
rogate parameters, importantly survival was dramatically
enhanced and despite the severity of the model after
7 days 50% of the animals survived. When analysisng spe-
cific sources of ROS that may lead to sGC oxidation and
heme loss, we observed that in NADPH oxidase 4 (NOX4)
KO mice, P-VASP levels were dramatically increased ver-
sus wild-type mice.
Conclusion
Thus in stroke NOX4-derived oxidative stress may contri-
bute to sGC oxidation and haem loss and subsequent apo-
sGC activation represents a disease-specific therapeutic
intervention leading to blood- brain barrier stabilisation, a
substantial anti-inflammatory component and increased
survival.
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